Phase 3 switch to weekly oral islatravir + lenacapavir in virologically suppressed people with HIV-1

Phase 3, randomised, open-label trial of islatravir and lenacapavir in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 (FDA Snapshot). Started Jan 2025; status: active, not recruiting.